A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.

Recruiting

• Conditions: Nasopharyngeal Carcinoma; EBV Infection
• Interventions: Diagnostic Test: Proteomics technology and liquid biopsy

• Registration Number: NCT05682703
• Lead Sponsor: Nanfang Hospital, Southern Medical University

Brief Summary

The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. Therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-12
• Study Start: 2022-12-23
• Study First Submitted: 2023-01-04
• Study First Submitted QC: 2023-01-04
• Last Update Submitted: 2023-01-04
• Study First Posted: 2023-01-12
• Last Update Posted: 2023-01-12
• Primary Completion: 2025-11-20
• Study Completion: 2025-12-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with previous infection;
• Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard);
• Healthy people: Healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the Physical Examination Center of Southern Hospital.

Exclusion Criteria

1. People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes);
2. Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
3. Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease;
4. Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose>1.5 × Upper limit of normal value), mental illness and severe allergic history.
5. BMI is less than 18 or more than 25. -

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
EBV virus infector	Proteomics technology and liquid biopsy	QPCR/EBV antibody, diagnosed as EBV infection patient
nasopharyngeal carcinoma patients	Proteomics technology and liquid biopsy	Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)
Healthy people	Proteomics technology and liquid biopsy	healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism

Primary Outcome Measures

Name	Time	Method
Achieve the expected number of enrolled cases	3 years	Achieve the expected number of enrolled cases

Trial Locations

Locations (1)

Southern medical university; 🇨🇳 Guangzhou, Guangdong, China